Carvedilol to prevent decompensation of liver cirrhosis in patients with clinically significant portal hypertension stratified by novel non-invasive model
Xiaolong Qi,Chuan Liu,Hong You,Qing‐Lei Zeng,Wong YJ,Bingqiong Wang,Ivica Grgurević,Bingtian Dong,Wei Gou,Shenghong Ju,Hyung Joon Yim,Yu Qin,Masashi Hirooka,Hirayuki Enomoto,Amr Shaaban Hanafy,Zhujun Cao,Xiuli Dong,Young Kul Jung,Tae Hyung Kim,Yohei Koizumi,Yoichi Hiasa,Takashi Nishimura,Hiroko Iijima,C. Xu,Xinru Guo,Xianyong Lan,Changxiang Lai,Shirong Liu,Fang Wang,Ying Guo,Jiaojian Lv,Jie Li,Liting Zhang,Yuqing Wang,Erfu Dai,Qing Xie,Chuxiao Shao,Zhensheng Liu,Federico Ravaioli,Antonio Colecchia,Gao‐Jun Teng
DOI: https://doi.org/10.22541/au.169450109.98248913/v1
2023-01-01
Abstract:Objective: To develop a novel non-invasive model for CSPH, and investigate whether carvedilol could reduce the risk of decompensation in patients with high-risk CSPH stratified by the novel model. Methods: International multicenter observational study with a median follow-up time of 38 months. Three cohorts were included in study from 6 countries. In this study, a total of 1,304 patients were fulfilled diagnosis of liver cirrhosis. Patients were treated with carvedilol in longitudinal carvedilol-treating cohort. The primary outcome was the development of the first hepatic decompensation . Results: Six studies from the meta-analysis were involved (n=819), and LSM and platelet count (PLT) were identified as independent risk factors of CSPH, with pooled risk ratios of 1.10 (95% confidence interval [CI] 1.06-1.15) and 0.99 (95% CI 0.98-0.99). A novel model was established. In HVPG cohort (n=151), the areas under the receiver operating characteristic curve (AUC) of the novel model, ANTICIPATE model, and Baveno VII criteria for CSPH were 0.91 (95% CI 0.86-0.95), 0.80 (95% CI 0.73-0.87), and 0.83 (95% CI 0.77-0.89). The novel model narrows down the grey zone to 22.5%, significantly lower than 50.3%, using Baveno VII criteria (p<0.001). In follow-up cohort (n=1,102), the cumulative incidences (1.7% vs 2.5% vs 15.8%) of decompensation events were significantly different by using the novel model cutoff values of >0, 0 to -0.68 (medium-risk), and <-0.68 (p<0.001). In the carvedilol-treating cohort, the patients with high-risk CSPH stratified by the novel model (treating cohort, n=51) had significantly lower rates of decompensation than those of NSBBs untreated patients with high-risk CSPH (n=613 before propensity score matching [PSM], n=102 after PSM, all p<0.05). Conclusion: A novel model provides stratification for CSPH and decompensation in patients with liver cirrhosis. Treatment with carvedilol significantly reduces the risk of decompensation among high-risk CSPH patients stratified by the novel model.